Recombinant Human Thrombopoietin Treatment Promotes Hematopoiesis Recovery in Patients with Severe Aplastic Anemia Receiving Immunosuppressive Therapy

Table 2

Hematological response to patients treated with and without rhTPO.

Time	Response	Patients with rhTPO, number (%)	Patients without rhTPO, number (%)	value
At 3 months	Total	17 (42.5%)	11 (22.9%)	0.0665
	CR	3 (7.5%)	1 (2.1%)
	PR	14 (35%)	10 (20.8)
At 6 months	Total	25 (62.5%)	20 (41.6%)	0.0579
	CR	8 (20%)	5 (10.4%)
	PR	17 (42.5%)	15 (31.2%)
At 9 months	Total	27 (67.5%)	23 (47.9%)	0.0847
	CR	10 (25%)	7 (14.6%)
	PR	17 (42.5%)	16 (33.3%)

CR: complete response; PR: partial response.